Targeting liver mitochondria to treat MASLD/MASH and cardiometabolic disease
Insulin resistance is a critical factor in the pathogenesis of type 2 diabetes. In addition insulin resistance plays a key role in the pathogenesis of MASLD/MASH, heart disease, obesity-associated cancers and Alzheimer’s disease. In this lecture I will review recent studies that have demonstrated the safety and efficacy of liver-targeted mitochondrial uncoupling agents to treat these diseases in both animal models and humans with MASLD/MASH and cardiometabolic disease. I will also review some novel 13C NMR and LC-MS/MS methods (PINTA and Q-Flux) that we have recently developed to assess rates of hepatic mitochondrial oxidation and anaplerotic fluxes in vivo.
Date:
Wednesday, 20 March, 2024 - 15:00 to 16:00
Event location:
MRC MBU, Level 7 Lecture Theatre, The Keith Peters Building, CB2 0XY